SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity
Condition(s):OtotoxicityLast Updated:March 17, 2021Enrolling by invitation
Hide Studies Not Open or Pending
Condition(s):OtotoxicityLast Updated:March 17, 2021Enrolling by invitation
Condition(s):Drug-induced Ototoxicity in Peritoneal Dialysis PatientsLast Updated:May 27, 2010Completed
Condition(s):Cisplatin Ototoxicity; Hearing LossLast Updated:October 9, 2019Completed
Condition(s):Ototoxicity; Hearing LossLast Updated:June 8, 2010Completed
Condition(s):Hearing Loss; OtotoxicityLast Updated:December 21, 2007Unknown status
Condition(s):OtotoxicityLast Updated:March 23, 2022Recruiting
Condition(s):Ototoxicity; Unspecified Childhood Solid Tumor, Protocol SpecificLast Updated:March 13, 2017Completed
Condition(s):Osteosarcoma; Nephrotoxicity; OtotoxicityLast Updated:March 16, 2020Completed
Condition(s):Ototoxicity; Unspecified Adult Solid TumorLast Updated:March 7, 2014Completed
Condition(s):Medulloblastoma; Ototoxicity; Anaplastic Medulloblastoma; Large Cell MedulloblastomaLast Updated:May 19, 2022Not yet recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.